510(k): Cardiac AI’s Billion Dollar De-Risking Strategy

Most people see FDA clearance for cardiac AI software as just a tax you have to pay to get to market. That’s a huge miscalculation. For VCs and investors who actually get it, the 510(k) regulatory path is a serious competitive weapon and a major moat. Looking at the real-world economics and operational work involved shows how a smart regulatory plan isn’t about compliance, it’s about de-risking the entire investment and locking in a market advantage before your competitors even get started.

The 510(k) Pathway: A Commercial Catalyst, Not Just Compliance

For cardiac AI software (what the FDA calls Software as a Medical Device or SaMD), the 510(k) is the main road to market, where you have to prove your tech is “substantially equivalent” to something already out there. But don’t be fooled by the simple description. Choosing the right predicate device and building the submission package has huge commercial consequences. Let’s talk timeline. Getting a 510(k) for AI/ML SaMD isn’t fast, with recent median review times sitting at 144 to 155 calendar days, and that’s after you submit. This figure doesn’t even include the weeks or months your file might be on hold while you scramble to answer FDA questions, which is why the real-world calendar time for a clean submission is more like 4 to 9 months, with complex cases going even longer. Every day of delay burns cash and pushes out your first dollar of revenue. Now for the cost. Getting a 510(k) done right means hiring regulatory consultants, and for digital health startups, their fees alone can swing from $15,000 to over $150,000 based on your device’s complexity. All in, with FDA user fees and testing, you’re looking at a total bill between $30,000 and $500,000+, and that’s before paying your own team. This is a big check to write, but it’s an investment that validates your AI’s safety, opens the door to getting paid by insurers, and earns trust from the doctors and hospitals who will actually use it.

Strategic Implications: Building a Regulatory Moat

A 510(k) clearance does more than just approve one product. It lets you define the market. Look at what companies like Viz.ai and Aidoc have done. Viz.ai didn’t just get one 510(k) for its AI-powered stroke detection and triage software. They got a series of them. Each new clearance let them plug their software into more parts of the acute care workflow, from the ER to the stroke unit which expanded their market and made their tool indispensable. Once a hospital has integrated Viz.ai’s triage system and trained its staff, the switching costs become enormous, that’s a real network effect built on regulatory wins. Their strategy was about getting approvals that systematically expanded how and where their tech was used, making it part of the hospital’s standard operating procedure. Aidoc is playing a similar game by integrating its AI triage workflows across different types of imaging under FDA guidance. They’ve built an entire platform on a foundation of separate clearances, letting them sell a single solution for multiple clinical problems like pulmonary embolism or intracranial hemorrhage. For a competitor with just one single-point solution, how do you even begin to compete with that? You can’t. That’s a regulatory moat. Aidoc’s FDA clearances

The Cost-Benefit of Regulatory Pathways: 510(k) vs. De Novo

The 510(k) is usually the way to go because it’s faster and more predictable. But what if your cardiac AI is genuinely new, with no existing predicate device to compare it to? Then you’re looking at a De Novo classification. This path is for low-to-moderate risk devices that are first of their kind. It’s a much heavier lift. The timeline stretches to 9-12 months or longer, and you’ll need to produce much more clinical data from larger prospective studies to prove your device is safe and effective. The submission fees aren’t that different, but the cost of generating that novel clinical data can be huge. The payoff, though, can be worth it. For an AI-native company with a genuinely new diagnostic tool, a successful De Novo means you get to create a whole new regulatory category. You become the predicate. Anyone who comes after you has to prove they are substantially equivalent to you. For investors, this creates incredible long-term defensibility for the startup’s technology.

The AI-Native Advantage: From Concept to Clearance

An AI-native company is built differently from the ground up, its core product, data pipelines, and entire business are centered on AI. This gives them a real edge with regulators. Why? Because the things the FDA wants to see for AI/ML devices, high-quality data, a solid model, and clear clinical use, are already part of their core development process. Hello Heart is a good illustration of this principle in action, even though it’s in digital therapeutics for heart health, not diagnostics. Their platform was built from the start to operate within clinical guardrails and produce evidence of efficacy from real patient data. That deep, structural commitment to data-driven validation makes the whole regulatory process smoother and cheaper. They generate the exact kind of evidence the FDA asks for just by operating their business. This is a world away from “AI health apps” that are often just old solutions with a poorly validated AI model slapped on top. Investors need to see this difference to tell a real, regulatable medical device company from a speculative app with an ‘AI’ sticker. Hello Heart’s clinical evidence

Methodology and Source Note

The information here comes from reviewing the public FDA 510(k) clearance databases, official FDA guidance docs on AI/ML devices, and reports from top digital health regulatory consultants. The timeline and cost figures are based on aggregated industry data and interviews. We’ve used companies like Viz.ai and Aidoc as examples because their public FDA filings and market activity show these strategies in action. FDA 510(k) database search The FDA 510(k) clearance pathway for cardiac AI software has plenty of economic and strategic angles. Any investor or VC who still sees regulatory as a checkbox instead of a core part of the commercial plan is going to get burned. The companies that win are the ones that plan their regulatory submissions to build a fortress around their business, using each clearance to get into more hospitals and shut out competitors. These are the better investments. How a company handles the FDA tells you almost everything you need to know. A team that can get through these pathways cleanly and strategically isn’t just good at paperwork, it’s a sign of a mature, well-run AI health company that knows how to execute.